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ing day 4 of infection. LD50 = 300 mg!kg). placebo or uninfected controls.
The pathology and microvasculature were blindly scored. and whole heart
norepinephrine (NE) content determined by HPLC. The mean cardiac NE and
pathological scores on day 28 (cardiomyopathy stage) are:
Chlor Placebo Unlnfected
Ilg/kg/min. ic). and subjected to four 8 minute periods of regional ischemia
(LAD occlusion) and reperfusion, Myocardial segment shortening (55) was
monitored throughout the stunning protocol and for 2 hours following the fi-
nal occlusion. Results: (55. % of baseline. ' p < 0,05 vs. saline. t p < 0,05 vs,
corresponding dose of GP531 alone):
NE (nM/L)
Path Score
5362 ± 389*
1.3 ± 0.6*
3382 ± 170
30 ± 0.1
5719 ± 60
00 ± 0.0
Treatment Baseline Occlusion 4 Reperfusion
1 hr 2 hr
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There was also significant amelioration of microvascular spasm in the Chlor
treated hearts. The mortality decreased from 42% (20/48) to 32% (14/44. p <
0.05).
We conclude that ganglionic blockade prevents the reduction in cardiac
norepinephrine levels in this murine model of myocarditis-cardiomyopathy.
Blocking sympathetic activation can significantly reduce the mortality. patho-
logical damage and microvascular angiopathy in the multifactorial process
leading from initial cardiac damage to the development of cardiomyopathy.
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8SPT + GP531 (10. n ~ 4)
CONTROL
DCM
OCM/ACEI
OCM/AT-BLOCK
, p < 0.05 vs. saline. t p < 0.05 vs, corresponding dose of GP531 alone
*p < 0.05 vs CONTROL. +p < 0,05 vs DCM
MYO membrane potential at the end of MYO contraction increased with
DCM and DCM/ACEI (4.9 ± 1.9*.4.4 ± 2.4*mV) compared to CONTROL (0.8
± 0.3 mY) but was normalized with DCM/AT-BLOCK (1.4 ± 0.9 mY). Thus.
ACEI during the progression of DCM improved MYO function whereas AT-
BLOCK had selective effects on MYO electrophysiology.
Summary: These findings suggest that ACEI and AT-BLOCK have unique
and different mechanisms of action with cardiomyopathic disease.
Differential Effects of Chronic Angiotensin
Converting Enzyme (ACE) Inhibition and Angiotensin
II (AT-II) Receptor (AT1 AT-II) Blockade on Myocyte
Excitation and Contraction In Dilated
Cardiomyopathy
Rupak Mukherjee, Henry H, Holzgrefe, James R, Powell. William H. Koster, Francis
G. Spinale. Med Univ ofSouth Carolina, Chas. SC; Bristol Myers Squibb Research
Institute. Princeton. NJ
AT-II production and AT1 AT-II receptor activation have been suggested to
contribute to the progression of dilated cardiomyopathy (DCM). However.
the direct effects of chronic ACE inhibition (ACEI) or specific ATl AT-II re-
ceptor blockade (AT-BLOCK) on myocyte (MYO) electrophysiology and con-
tractility with the progression of DCM are unknown. Accordingly. simulta-
neous indices of isolated MYO membrane potential (resting; RMP. max up-
stroke velocity; Vmax, time to 90% repolarization; APD90) and contraction
(percent; MYO% and velocity of shortening; MYOVEL) were obtained from
4 groups of dogs (n = 6/group): DCM; chronic pacing (216bpm; 4 weeks).
DCM/ACEI; chronic pace and concomitant ACEI (fosinopril; 30 mg!kg BID).
DCM/AT-BLOCK; chronic pace and treatment with a specific non-peptide AT1
AT-II antagonist (BMS-186295; 30 mg!kg BID), and CONTROL.
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GP531 improved functional recovery in stunned myocardium. and this was
prevented by adenosine receptor blockade with 8SPT, GP531 did not affect
baseline hemodynamics or myocardial function. confirming receptor binding
studies indicating that it is not a direct ADO receptor agonist. We conclude
that GP531 protects the myocardium from ischemic injury in anesthetized
pigs primarily via regulation of endogenous adenosine,
B
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1727-21 Changes in Left Ventricular Mechanics and
Energetics in Canine Microembolization Model of
Heart Failure
Koji Todaka. Shu-Ming Zhu. Anguo Gu. Richard Stemett. Daniel Burkhoff. Columbia
University. New York. NY
Myocardial mechanics and energetics have been shown previously to be
markedly abnormal in a canine model of pacing induced heart failure. How-
ever. whether those abnormalities pertain to other. more clinically relevant
forms of heart failure is unknown. To investigate this question, heart failure
was created by ischemic damage in 6 dogs (CHF group) that underwent re-
peated coronary microsphere injections over 2 months resulting in afinal area
ejection fraction (aEF) of 34 ± 4%. A control group of 6 normal dogs had
an aEF of 46 ± 8%, Hearts of these animals were isolated, cross-perfused
and balloons placed in the LV to control volume. We measured the LV end-
systolic (ESPVR) and end-diastolic (EDPVR) pressure-volume relations and
the relationship between oxygen consumption (mV02) and pressure-volume
area (PVA). p-responsiveness of the CHF group was significantly depressed
compared to control as assessed by the increased amount of isoproterenol
required to increase peak isovolumic LV pressure by40% (72 ± 36 vs. 29 ± 14
pg/min. p < 0.05) providing pharmacologic evidence of the heart failure state,
CHF hearts had a depressed and dilated LV as assessed by the ESPVR slope,
Ees, and volume axis intercept, Yo, (both normalized to LV mass) compared
to control (TABLE). EDPVR of CHF hearts was shifted to the right compared to
control. Systolic and diastolic stress-strain relationships. estimated from the
pressure-volume relations. were similar in the two groups. These data sug-
gest that with the degree of chronic ischemic damage achieved, there was
systolic LV chamber dysfunction and chamber remodeling but not myocar-
dial property changes in surviving muscle. The mVOz-PVA relation in CHF
hearts had smaller mV02-intercept (B) than control with no change in the
slope (A) (TABLE), This contrasts with a previous report using a rapid pacing
CHF model in which myocardial strength was decreased, A was decreased
and B was unchanged. These data suggest that 1) in spite of the notable
structural and functional changes in chamber mechanics. energetic aspects
of the failing heart remained unaltered in this model and 2) conclusions about
myocardial energetics in CHF are model dependent.
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1727-31 Regulation of Endogenous Adenosine Improves
Myocardial Functional Recovery Following
Ischemia/Reperfusion Injury
Michael A, Kurz. Kevin Mullane. Mark A. Young. Gensia Inc., San Diego, CA
Adenosine (ADO) has been shown to be cardioprotective following is-
chemia/reperfusion injury. but its utility is limited by profound hemody-
namic side-effects. Therefore, we studied the effects of a novel ADO reg-
ulating agent, GP531 (5-amino-l-p-D-(5-benzylamino-5-deoxy-ribofuranosyl)
imidazole-4-carboxamide), on functional recovery following myocardial stun-
ning in pigs. GP531 does not bind to ADO A1. A2. or A3 receptors, but
increases local endogenous ADO concentrations, Anesthetized pigs were
treated with GP531 (lor 1Ollg!kg/min, iv) orvehicle (saline) in the presence or
absence of the ADO-receptor antagonist 8-sulfophenyltheophylline (8SPT. 83
* p < 0.05. ** P < 0.01 vs. Control by ANCOVA
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Differential Role of Circulating and Ventricular ANP
as a Marker for Cardiac Filling Pressures and
Ventricular Remodeling In a Model of Pacing Induced
Heart Failure and Cardiac Hypertrophy
Margaret M. Redfield. Tracy L, Stevens, Lawrence L. Aarhus, Lane M. Meyer, John
C. Burnett. Jr.. Mayo Clinic. Rochester, MN
Previous studies have suggested that circulating atrial natriuretic peptide
(ANP) is a marker for cardiac filling pressures and ventricular myocardial pro-
duction of ANP a marker for ventricular hypertrophy and/or dilatation. To ad-
dress the role of circulating ANP as a marker for ventricular hypertrophy and
dilatation as compared to cardiac filling pressures, we developed a new ca-
nine model of pacing induced heart failure that in contrast to previous pacing
models produces sustained ventricular hypertrophy. This involves gradually
increasing the pacing rate from 180 to 240 bpm over 30 days (PROG PACE,
n = 5) followed by 4 weeks of recovery (REC. n = 6). Four NORMAL dogs
served as controls, Diastolic dimension (LVEDd) and EF were assessed by
echo, LV mass was assessed by echo prior to rapid ventricular pacing (pre-
RVP) in the PROG PACE (4.2 ± 0.2 g/kg) and REC (4,7 ± 0.2 g/kg) dogs. LV
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